Pulmonx Q3 2026 Earnings Conference Call - PULMONX CORP

Explicit Guidance:

• Full Year 2026 Revenue: Reiterated guidance of $90 million to $92 million, noting confidence in achieving this range as Q3 growth (6% YoY) is expected to continue into Q4.
• Full Year 2026 Gross Margin: Expected to be approximately 77%, driven by persistent supply chain cost efficiencies and a lower mix of distributor sales internationally.
• Full Year 2026 Operating Expenses: Expected to range between $108 million and $109 million, inclusive of approximately $14 million in non-cash stock-based compensation.
• Full Year 2026 Cash Burn: Expected to be roughly $22 million, representing a 30% reduction from 2025 burn rates.
• 2027 Outlook: Management explicitly refrained from providing specific 2027 financial guidance or revenue ranges, stating it is premature to do so given the recent return to growth.
• Share Metrics: No specific targets provided for share count, buybacks, or dividends; management indicated a path to cash flow break-even supported by current capital access ($20 million undrawn on credit facility).

Business-Segment Outlook:

• U.S. Business: Confidence in continued growth driven by a rebuilt sales force where substantially all territories are filled; focus on ramping productivity of new and promoted reps (TAMs to Territory Managers) and "same-store sales" rather than just new account acquisition.
• International Business: Growth expected to persist; excluding China, international markets grew ~9% in Q3.
• China Region: Commercial activity resumed following renewal of registration certificates; shipments to the distributor expected to resume by early 2027 (variability noted between Q4 2026 and early 2027). China is expected to contribute roughly 2% of global revenue and is anticipated to be a "lumpy" distributor market.
• Product Pipeline (AeroSeal/Convert2): The Convert2 IDE trial enrollment is on track to complete in the back half of 2027. AeroSeal is projected to expand the Total Addressable Market (TAM) by roughly 20% globally. Commercial launch in Europe is expected in 2027 (limited launch phase), with material revenue contributions anticipated in 2028.
• TAM Expansion: AeroSeal is identified as a key tool for expanding the addressable market beyond current Zephyr valve indications.

Market and Competitive Outlook:

• Demand Trends: Strong scientific engagement observed at recent medical meetings (European Respiratory Society, AABIP) regarding bronchoscopic lung volume reduction and endobronchial valves.
• Pricing & Margins: Gross margins expected to remain above 75% for the foreseeable future despite the inclusion of China (which carries a margin drag) and potential inflation.
• Competitive Position: Management views the market opportunity as "substantial" and is focused on penetrating existing accounts via a "near-to-far" strategy, prioritizing high-quality valve programs and physician education.
• Salesforce Productivity: Expectation that the new sales team, including junior reps promoted to full-time roles, will drive continued productivity and same-store sales growth.

Macro / Industry Outlook:

• China Regulatory/Tariff Context: Previous administrative challenges and tariff discussions led to a preparatory rush in China revenue (reaching 10% of revenue in one quarter); current outlook normalizes this to ~2% share.
• Currency: Q3 revenue growth was driven on both reported and constant currency bases; international growth was 6% on a constant currency basis.
• Interest Rates/Inflation: No specific macro rate forecasts given; management anticipates operating expenses may increase slightly due to inflation but expects no meaningful structural cost increases.
• Clinical Landscape: Market interest is shifting toward multidisciplinary approaches to severe COPD management and expanding the patient pathway for endobronchial valves.

Strategic Initiatives:

• Commercial Expansion: Successfully filled substantially all open U.S. sales positions; ongoing opportunistic expansion of territories where geography or revenue complexity dictates, targeting ~40 new treating centers annually.
• Clinical Development: Accelerating the Convert2 IDE trial for AeroSeal to enable TAM expansion.
• Digital Marketing: Continued optimization of digital advertising to reduce cost per patient engagement and increase yield to treatment.
• Operational Restructuring: Cost reduction efforts initiated at the start of 2026 reduced recurring costs by 10% without impacting commercial/R&D investments; operating leverage is now expected to be driven by top-line growth.
• Credit Facility: Credit facility restructured earlier in 2026 with maturity extended to 2031; includes access to $20 million in undrawn capital subject to revenue milestones.

Risks and Headwinds to Outlook:

• Clinical Trial Execution: Timelines for the Convert2 IDE trial completion depend on successful enrollment in the back half of 2027.
• Market Volatility: China market performance is characterized as "lumpy" due to its distributor model, creating unpredictability in revenue timing.
• Sales Force Tenure: Mean/median tenure of the U.S. sales organization is relatively low (1.2–1.8 years); variability exists in the time required to bring new hires up to full quota-carrying speed.
• Regulatory/Tariff: Continued regulatory hurdles or tariff discussions could impact international expansion timing.
• Forward-Looking Statement Disclaimer: Actual results may differ materially due to risks and uncertainties outlined in SEC filings (Form 10-Q).

Management Tone on the Future:

• Confidence Level: Highly confident ("increasingly confident," "greater conviction," "great confidence") in the execution of the current strategy and the return to sustainable revenue growth.
• Strategic Focus: Emphasis on "disciplined execution," "refining execution," and "operating leverage" rather than aggressive new financial targets for 2027.
• Cautious Optimism: While committed to sustained double-digit growth long-term, management avoided setting specific 2027 numbers, deeming it "premature" immediately after returning to growth in Q3 2026.
• Momentum: Strong belief that the trends observed in Q3 (U.S. and International growth) will persist into Q4 and 2027.

Miscellaneous:

• Capital Structure: Cash and cash equivalents ended Q3 2026 at $52.7 million; strong balance sheet with debt maturity extended to 2031.
• Stock Compensation: Expected to be $14 million for the full year 2026.
• Net Loss Trend: Net loss narrowed 40% YoY in Q3 to $8.4 million; adjusted EBITDA loss narrowed nearly 60% to $3.5 million.
• Employee Sentiment: CEO praised employee engagement and consistent execution as key drivers of the return to growth.